Crossover Comparison of MultiHance and Dotarem

Last updated: November 14, 2016
Sponsor: Bracco Diagnostics, Inc
Overall Status: Completed

Phase

4

Condition

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT02070380
MH-148
  • Ages > 18
  • All Genders

Study Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are at least 18 years of age or older

  • Are able to give written informed consent and are willing to comply with the protocolrequirements

  • Are scheduled to undergo MRI

  • Are willing to undergo two MRI procedures within 14 days

  • Have confirmed or are highly suspected to have brain tumor(s) (primary or secondary),as determined by:

  • Clinical/neurological symptomatology;

  • Diagnostic testing, such as CT or previous MRI examinations; or

  • Have had recent brain surgery and are to be evaluated for recurrence

Exclusion

Exclusion Criteria:

  • Are pregnant or lactating females. Exclude the possibility of pregnancy:

  • By testing on site at the institution within 24 hours prior to the start of eachinvestigational product administration; or

  • By history (i.e., tubal ligation or hysterectomy); or

  • Post menopausal with a minimum of 1 year without menses

  • Have any known allergy to one or more of the ingredients in the investigationalproducts, or have a history of hypersensitivity to any metals

  • Have congestive heart failure (class IV according to the classification of the NewYork Heart Association)

  • Have suffered a stroke within a year

  • Have received or are scheduled to receive any other contrast medium in the 24 hourspreceding through the 24 hours following Exam 1, and in the 24 hours preceding throughthe 24 hours following Exam 2

  • Have received or are scheduled to receive an investigational compound and/or medicaldevice within 30 days before admission into the present study, through the 24 hourspost-administration of the second investigational product

  • Have moderate-to-severe renal impairment, defined as Glomerular Filtration Rate (GFR)/estimated GFR < 45 mL/min

  • Have been previously entered into this study

  • Have received or are scheduled for one of the following:

  • Surgical or chemotherapeutic treatment within three weeks prior to the firstexamination or between the two examinations

  • Initiation of steroid therapy between the two examinations

  • Radiosurgery between the two examinations

  • Have any contraindications to MRI such as a pace-maker, magnetic material (i.e.,surgical clips) or any other conditions that would preclude proximity to a strongmagnetic field

  • Are suffering from severe claustrophobia

  • Have any medical condition or other circumstances which would significantly decreasethe chances of obtaining reliable data, achieving study objectives, or completing thestudy and/or post-dose follow-up examinations

Study Design

Total Participants: 179
Study Start date:
February 01, 2014
Estimated Completion Date:
March 31, 2015

Study Description

This crossover study aims at a comparison between 0.1 mmol/kg MultiHance and 0.1 mmol/kg Dotarem, between 0.05 MultiHance and 0.1 mmol/kg Dotarem in terms of diagnostic preference at CE-MRI in brain tumor patients to show superiority of MultiHance.

Connect with a study center

  • Samaritan Health Services

    Corvallis, Oregon 97330
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.